Why Kezar Life Sciences Stock Is Soaring Today
Shares of Kezar Life Sciences (NASDAQ: KZR) were soaring 36.1% as of 11:03 a.m. EST on Tuesday. The big gain came after the company announced interim results on Monday from a phase 2 study evaluating KZR-616 in treating autoimmune disease lupus nephritis.
With the huge move for the biotech stock today, it's not surprising that Kezar's results were really good. The company reported that four out of five patients receiving KZR-616 in the phase 2 study achieved either a partial or complete renal response.
Image source: Getty Images.
Source Fool.com
